Ready or not? Lung cancer diagnosis in 2015

被引：2
作者：
Jao, K. [1 ]
Labbe, C. [1 ]
Leighl, N. B. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2015年 / 22卷 / 04期
关键词：
GROWTH-FACTOR RECEPTOR; TRANSBRONCHIAL NEEDLE ASPIRATION; OF-AMERICAN-PATHOLOGISTS; ENDOBRONCHIAL ULTRASOUND; INTERNATIONAL-ASSOCIATION; CLINICAL-PRACTICE; ALK; EGFR; CHEMOTHERAPY; CARBOPLATIN;
D O I：
10.3747/co.22.2647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：239 / 242
页数：4
相关论文
共 34 条
  • [1] [Anonymous], CAN CANC STAT 2014
  • [2] Boag AH, 2014, BEST PRACTICES ONCOL
  • [3] Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
    Burdett, S.
    Stephens, R.
    Stewart, L.
    Tierney, J.
    Auperin, A.
    Le Chevalier, T.
    Le Pechoux, C.
    Pignon, J. P.
    Arriagada, R.
    Higgins, J.
    Johnson, D.
    van Meerbeeck, J.
    Parmar, M.
    Souhami, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4617 - 4625
  • [4] Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non-Small-Cell Lung Cancer in a Publicly Funded Health Care System
    Ellis, Peter M.
    Verma, Sunil
    Sehdev, Sandeep
    Younus, Jawaid
    Leighl, Natasha B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (09) : 1136 - 1141
  • [5] Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009
    Houston, Keisha A.
    Henley, S. Jane
    Li, Jun
    White, Mary C.
    Richards, Thomas B.
    [J]. LUNG CANCER, 2014, 86 (01) : 22 - 28
  • [6] Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada
    Ionescu, D. N.
    [J]. CURRENT ONCOLOGY, 2013, 20 (04) : 220 - 226
  • [7] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    Johnson, DH
    Fehrenbacher, L
    Novotny, WF
    Herbst, RS
    Nemunaitis, JJ
    Jablons, DM
    Langer, CJ
    DeVore, RF
    Gaudreault, J
    Damico, LA
    Holmgren, E
    Kabbinavar, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191
  • [8] Personalized medicine for lung cancer: new challenges for pathology
    Kerr, Keith M.
    [J]. HISTOPATHOLOGY, 2012, 60 (04) : 531 - 546
  • [9] Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
    Kim, Lucia
    Tsao, Ming Sound
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (04) : 1011 - 1022
  • [10] Biomarkers that currently affect clinical practice in lung cancer: EGFR ALK, ET, ROS-1, and KRAS
    Korpanty, Grzegorz J.
    Graham, Donna M.
    Vincent, Mark D.
    Leigh, Natasha B.
    [J]. FRONTIERS IN ONCOLOGY, 2014, 4 : 1 - 26
1234